For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

Implantable cardioverter-defibrillator therapy in patients with Brugada syndrome is effective for prevention of fatal arrhythmias.

The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

A scientific statement regarding risk-based primary prevention of heart failure has been published by the American Heart Association.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Both dual use of traditional and e-cigarettes and exclusive cigarette use are associated with higher toxicant exposure than exclusive e-cigarette use.

The Food and Drug Administration (FDA) has cleared the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD).

Exposure to antihypertensives, NSAIDs, and statins showed a strong correlation with older Parkinson disease age at onset, while smoking and family history, however, correlated with younger age at ...

A study was conducted to examine gender and sociodemographic disparities in ICD access for patients with high-risk heart failure.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics Lic ...

A scientific statement has been published by the American Heart Association regarding the effect of sleep health on cardiometabolic health.